"uuid:ID","id","name","rationale","instanceType","description","label"
"1175ba8f-64ae-4464-995a-f4ca8357d5a9","StudyDesign_1","Study Design 1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign","The main design for the study",""
